Parabilis reports high response rate for zolucatetide in desmoid tumors
Parabilis Medicines reported updated Phase 1/2 data showing a 72.2% objective response rate at 32 weeks for desmoid tumor patients who started zolucatetide at 450 mg or higher. Among 46 response-evaluable patients at those doses, disease control was 100% with no progression, and treatment-related side effects were mostly low-grade with no discontinuations. The company said it has aligned with the FDA on a placebo-controlled Phase 3 trial planned for the first half of 2027, with topline results expected in 2029.
" then paragraph. Need exactly format. Could include blank line between paragraphs? Fine. Need under 120 words total expanded. We have 116. Need maybe count "1/2" as one? okay. Context under 90. Let's count context: If1 confirmed2 in3 later4 trials5, the6 results7 could8 affect9 patients10 with11 desmoid12 tumors13 by14 adding15 a16 potential17 treatment18 option19, and20 may21 influence22 how23 clinicians24 discuss25 risks26 and27 benefits28. Families29 and30 caregivers31 could32 face33 new34 decisions35 about36 access37 and38 long-term39 monitoring40. Health41 systems42 and43 payers44 may45 need46 to47 assess48 cost49 and50 coverage51 if52 approval53 follows54. The55 planned56 Phase57 3 58 timeline59 means60 most61 societal62 effects63 would64 likely65 be66 years67 away68. Good 68. "would likely" not could/may?